Track record and experience are key drivers of success in drug development. Our experienced, multi-disciplinary team have overseen successful new drug application (NDA) programs. Some have built, scaled and exited drug development companies. Others have supported major M&A and licensing transactions across the sector. This experience has all been instrumental in building our risk-adjusted portfolio and will drive continued development and value creation.
With over thirty years’ investment experience, specialising in private equity and venture capital, Catherine has led major UK financial organisations which support technology-driven businesses, including in the life sciences. In her most recent role as CEO of British Patient Capital, Catherine has been at the heart of investment in innovation.
Experienced in academia, pharma, and CROs, specialising in oncology and immunology research. Skilled in managing early-stage preclinical projects, with expertise in novel immuno-oncology targets to redirect the immune system against tumours.
Brian has more than 30 years of drug discovery experience, within Pharma (Merck/Novartis), Biotech (Cedilla Tx) and Venture (Third Rock), spanning all major therapeutic areas. He has been responsible for >20 INDs and involved in two small-molecule programmes leading to marketed drugs (Fabhalta® and Isturisa®).
For more information on our pipeline or individual programmes please get in touch with us